MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the understanding and treatment of urea associated skin diseases that has puzzled scientists for decadesMC2-25 CKD uses a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skinMC2-25 CKD has the potential to become the world’s first approved treatment for pre-dialysis Chronic Kidney Disease-associated Pruritus (CKD-aP), a debilitating condition thought to affect a significant proportion of the ~800 million people globally who suffer from Chronic Kidney Disease (CKD)111 patients enrolled in the multi-center trial across Europe with topline results expected in Q2 2024 Copenhagen, December 7th, 2023 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory conditions, today announced it has completed enrollment in its European Phase 2 trial assessing the safety and efficacy of MC2-25 CKD, an innovative new drug candidate for the treatment of urea associated skin diseases, incl.

MC2 Therapeutics宣布完成MC2-25 Ph2慢性肾脏病相关瘙痒症试验MC2-25 CKD是一流的候选药物，是了解和治疗尿素相关皮肤病的潜在突破，这一直困扰着科学家对decadesMC2-25 CKD使用二肽作为异氰酸酯清除剂来抑制氨基酸和尿素的氨甲酰化皮肤中的蛋白质MC2-25 CKD有可能成为世界上第一个被批准用于透析前慢性肾病相关瘙痒症（CKD aP）的治疗方法，这一令人衰弱的状况被认为会影响全球约8亿患有慢性肾病（CKD）的患者中的很大一部分。参加欧洲多中心试验的111名患者预计将于2024年第二季度（2023年12月7日，哥本哈根）获得最终结果–MC2治疗，一家商业阶段的生物技术公司专注于在免疫介导和炎症条件下开发新的治疗范例，今天宣布已完成其欧洲2期试验的注册，该试验评估了MC2-25 CKD的安全性和有效性，MC2-25 CKD是一种创新的候选新药，用于治疗尿素相关皮肤病，包括。

CKD-aP Stage 5 (dialysis) and stages 3 and 4 (pre-dialysis), the latter segment having no approved treatment options. MC2-25 CKD presents a potential breakthrough in the understanding and treatment of urea associated skin diseases that has puzzled scientists for decades. It is a totally novel treatment paradigm based on a di-peptide selected to inhibit carbamylation of amino acids and proteins in skin, which is believed to be the causal factor in CKD-aP.

CKD aP第5阶段（透析）和第3和第4阶段（透析前），后一阶段没有批准的治疗选择。MC2-25 CKD在理解和治疗尿素相关皮肤病方面取得了潜在的突破，几十年来一直困扰着科学家。这是一种基于二肽的全新治疗范例，该二肽被选择用于抑制皮肤中氨基酸和蛋白质的氨甲酰化，这被认为是CKD aP的致病因素。

MC2-25 CKD has an attractive treatment profile based on convenience and tolerability and has the potential to provide relief f.

MC2-25 CKD具有基于便利性和耐受性的有吸引力的治疗特征，并且有可能提供缓解f。